Dihydrodipyrazolopyridinylbenzamide and -sulfonamide inhibitors of B7-1
AssigneeWyeth
InventorsNeal Jeffrey Green, Jason Shaoyun Xiang, Audrey Molina Davies, Lihren Chen
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of formula I and the use thereof for the immunotherapeutic treatment of transplant rejection or autoimmune disease. 1
Claims20
A compound of formula I
- 20
- wherein
- X is CO or SO2;
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R8, CONR9R10, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R11, NR12R13 or CN groups;
- R3 is H, F, Cl, Br or l;
- R4 and R5 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a
- C1-C6alkyl group optionally substituted with one or two CN, OR14, NR15 R16, CO2R17 or C3-C7cycloalkyl group,
- phenyl optionally substituted with one or two halogen, CN, OR14, NR15R16, CO2 R17, COR18, an optionally substituted C1-C6alkyl or an optionally substituted C2-C6alkenyl group,
- benzyl optionally substituted with one or two halogen, OR14, COR18, or a C1-C3alkyl group optionally substituted with one OR14 group, or
- pyridinyl optionally substituted with one or two halogen, OR14, NR15R16 or CO2R17 groups, or
- R4 and R5 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR19 or S;
- R6 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21, R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups;
- R8, R11, R17, R18 and R23 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- R9, R10, R12, R13, R15, R16, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R9 and R10 or R12 and R13 or R15 and R16 or R2, and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- n is O or an integer of 1 or 2;
- R14 is H, C1-C3alkyl or C1-C3haloalkyl;
- R19 is H or C1-C3alkyl;
- and
- R20 is a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A method for the treatment of an immune disorder related to or affected by the immune regulatory protein B7-1 which comprises providing a patient in need thereof an immunotherapeutically effective amount of a compound of formula
- 21
- wherein
- X is CO or SO2;
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R8, CONR9R10, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R11, NR12R13 or CN groups;
- R3 is H, F, Cl, Br or l;
- R4 and R5 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR14, NR15R16, CO2R17 or C3-C7cycloalkyl group,
- phenyl optionally substituted with one or two halogen, CN, OR14, NR15R16, CO2R17, COR18, an optionally substituted C1-C6alkyl or an optionally substituted C2-C6alkenyl group,
- benzyl optionally substituted with one or two halogen, OR14, COR18, or a C1-C3alkyl group optionally substituted with one OR14 group, or
- pyridinyl optionally substituted with one or two halogen, OR14, NR15R16 or CO2R17 groups, or
- R4 and R5 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR19 or S;
- R6 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21,R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups;
- R8, R11, R17, R18 and R23 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- R9, R10, R12, R13, R15, R16, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R9 and R10 or R12 and R13 or R15 and R16 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- n is 0 or an integer of 1 or 2;
- R14 is H, C1-C3alkyl or C1-C3haloalkyl;
- R19 is H or C1-C3alkyl;
- and
- R20 is a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- 22
- wherein
- X is CO or SO2;
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R8, CONR9R10, C3-C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R11, NR12R13 or CN groups;
- R3 is H, F, Cl, Br or l;
- R4 and R5 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two
- CN, OR14, NR15 μl6, CO2 μl7 or C3-C7cycloalkyl group,
- phenyl optionally substituted with one or two halogen, CN, OR14, NR15R16, CO2R17, COR18, an optionally substituted C1-C6alkyl or an optionally substituted C2-C6alkenyl group,
- benzyl optionally substituted with one or two halogen, OR14, COR18, or a C1-C3alkyl group optionally substituted with one OR14 group, or
- pyridinyl optionally substituted with one or two halogen, OR14, NR15R16 or CO2R17 groups, or
- R4 and R5 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR19 or S;
- R6 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21, R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups;
- R8, R11, R17, R18 and R23 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- R9, R10, R12, R13, R15, R16, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R9 and R10 or R12 and R13 or R15 and R16 or R21 and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- n is 0 or an integer of 1 or 2;
- R14 is H, C1-C3alkyl or C1-C3haloalkyl;
- R19 is H or C1-C3alkyl;
- and
- R20 is a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7Cyclo-heteroalkyl or heteroaryl group each optionally substituted;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A process for the preparation of a compound of formula Ia
- 23
- wherein
- R1 and R2 are each independently H, C1-C10alkyl optionally substituted with one or more halogen, hydroxy, C1-C4alkoxy, CO2R8, CONR9R10, C3C7cycloalkyl or optionally substituted phenyl groups, or
- phenyl optionally substituted with one to three halogen, hydroxy, C1-C6haloalkyl, C1-C4alkoxy, CO2R11, NR12R13 or CN groups;
- R3 is H, F, Cl, Br or l;
- R4 and R5 are each independently H, NH2, CH2CH2OCH2CH2OCH2CH2NH2 or a C1-C6alkyl group optionally substituted with one or two CN, OR14, NR15R16, CO2R17 or C3-C7cycloalkyl group,
- phenyl optionally substituted with one or two halogen, CN, OR14, NR15R16, CO2R17, COR18, an optionally substituted C1-C6alkyl or an optionally substituted C2-C6alkenyl group,
- benzyl optionally substituted with one or two halogen, OR14, COR18, or a C1-C3alkyl group optionally substituted with one OR14 group, or
- pyridinyl optionally substituted with one or two halogen, OR14, NR15R16 or CO2R17 groups, or
- R4 and R5 may be taken together with the atom to which they are attached to form an optionally substituted 5- to 7-membered ring optionally containing one double bond, a benzofused ring or an additional heteroatom selected from O, NR19 or S;
- R6 is phenyl optionally substituted with one to three halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR2,R22, CO2R23 or NR24R25 groups,
- cycloheteroalkyl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21, R22, CO2R23 or NR24R25 groups, or
- heteroaryl optionally substituted with one or more halogen, NO2, CN, hydroxy, C1-C6alkyl, C1-C6alkylthio, C1-C6haloalkyl, C1-C6alkoxy, phenyl, phenoxy, benzyl, benzyloxy, SOnR20, SO2NR21R22, CO2R23 or NR24R25 groups;
- R8, R11, R17, R18 and R23 are each independently H or a C1-C6alkyl, C3-C7 cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted;
- R9, R10, R12, R13, R15, R16, R21, R22, R24 and R25 are each independently H or a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cycloheteroalkyl or heteroaryl group each optionally substituted or each of R9 and R10 or R12 and R13 or R15 and R16 or R2, and R22 or R24 and R25 may be taken together with the nitrogen atom to which they are attached to form a 5- to 7-membered ring optionally containing another heteroatom selected from O, N or S;
- n is 0 or an integer of 1 or 2;
- R14 is H, C1-C3alkyl or C1-C3haloalkyl;
- R19 is H or C1-C3alkyl;
- and
- R20 is a C1-C6alkyl, C3-C7cycloalkyl, C1-C6haloalkyl, phenyl, C5-C7cyclo-heteroalkyl or heteroaryl group each optionally substituted which process comprises reacting a compound of formula II
- 24
- wherein R1, R2, R3 and R6 are defined hereinabove with an amine, HNR4R5, in the presence of an activating agent and a solvent.
Dependencies are inferred from the claim text.